A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

Inclusion Criteria: * Be at least 18 years of age. * Provided written informed consent. * Have a reported history of dry eye Have a history of use or desire to use eye drops for dry eye Exclusion Criteria: * Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) at Visit 1. * Be diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months. * Have any planned ocular and/or lid surgeries over the study period. * Have corrected visual acuity greater than or equal to +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit . * Have an uncontrolled systemic disease. * Be a woman who is pregnant, nursing or planning a pregnancy. * Be a woman of childbearing potential who is not using an acceptable means of birth control * Have a known allergy and/or sensitivity to the test article or its components. * Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study * Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of Visit 1 Be unable or unwilling to follow instructions, including participation in all study assessments and visits